UK markets close in 7 hours 10 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.33+0.07 (+0.85%)
At close: 4:00PM EDT
8.69 +0.36 (+4.32%)
Pre-market: 04:20AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.26
Bid0.00 x 4000
Ask0.00 x 4000
Day's range8.23 - 8.66
52-week range0.25 - 18.77
Avg. volume16,120,623
Market cap1.656B
Beta (5Y monthly)4.30
PE ratio (TTM)N/A
EPS (TTM)-0.27
Earnings date04 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.88
  • Motley Fool

    Is Now a Good Time to Buy Ocugen?

    In the coronavirus vaccine market, several players -- including Moderna and Pfizer -- are currently benefiting from a first-mover advantage. One of them is Ocugen (NASDAQ: OCGN), a company that partnered with India-based Bharat Biotech to develop and market a COVID-19 vaccine called Covaxin. Like many other meme stocks, shares of Ocugen have been highly volatile since the beginning of the year -- and a recent regulatory breakthrough in India sent the company's stock soaring through the roof.

  • Motley Fool

    Why Shares of Dynavax Technologies, Ocugen, and Valneva Are on the Move Today

    These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.

  • Motley Fool

    Is Ocugen Stock Heading for a Crash?

    Ocugen (NASDAQ: OCGN) shares took center stage earlier this year when the biotech joined the coronavirus vaccine race. The company partnered with India's Bharat Biotech to co-develop and co-commercialize Bharat's vaccine candidate -- Covaxin -- in the U.S. As a result, Ocugen shares soared as much as 763% in about six weeks. Now, some investors might be wondering if Ocugen will hang onto this positive momentum -- or whether the stock is heading for a crash.